Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01894061 : NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
PhasePhase 2
AgesMin: 22 Years Max: N/A
Inclusion Criteria:

- Patients with histologically confirmed glioblastoma or other grade IV malignant glioma
(i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam
fractionated radiotherapy and temozolomide chemotherapy.

- Patients with up to two prior recurrences are allowed.

- Karnofsky performance status =70.

- Patients must have the following laboratory values:

- Absolute neutrophil count (ANC) =1.5 x 10^9/L

- Platelets = 100 x 10^9/L

- Hemoglobin (Hgb) > 9 g/dL

- Serum total bilirubin: = 1.5 x ULN

- ALT and AST = 3.0 x ULN

- Serum creatinine = 1.5 x ULN

- Blood coagulation parameters: INR = 1.5

- Minimum interval since completion of radiation treatment is 12 weeks

- Minimum interval since last drug therapy:

- 3 weeks since last non-cytotoxic therapy

- 3 weeks must have elapsed since the completion of a non-nitrosourea-containing
chemotherapy regimen

- 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen.

- Patients must have signed an approved informed consent and authorization permitting
release of personal health information.

- Patients with the potential for pregnancy or impregnating their partner must agree to
follow acceptable birth control methods to avoid conception. The effects of
bevacizumab on developing fetus or nursing infant are not known. Female patients of
child-bearing potential must have a negative pregnancy test.

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast,
adequately treated stage I or II cancer from which the patient is in complete
remission. Patients with other prior malignancies must be disease-free for = three

- Patients must be maintained on a stable corticosteroid regimen from the time of their
baseline scan until the start of treatment and/or for at least 5 days before starting

Exclusion Criteria:

- Patients who have had previous treatment with bevacizumab, and or NovoTTF 100A system.

- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
intra-pelvic), open biopsy or significant traumatic injury = 4 weeks prior to starting
study drug, or patients who have had minor procedures, percutaneous biopsies or
placement of vascular access device =1 week prior to starting study drug, or who have
not recovered from side effects of such procedure or injury

- Patients with impaired cardiac function or clinically significant cardiac diseases,
including any of the following:

- History or presence of serious uncontrolled ventricular arrhythmias

- Any of the following within 6 months prior to starting study drug: myocardial
infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG),
Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient
Ischemic Attack (TIA), Pulmonary Embolism (PE)

- Uncontrolled hypertension (defined by a systolic blood pressure (SBP) = 160 mm Hg
or diastolic blood pressure (DBP) = 100 mm Hg while on anti-hypertensive

- Patients with cirrhosis, or active viral or nonviral hepatitis.

- Implanted pacemaker, defibrillator or deep brain stimulator, other implanted
electronic devices in the brain or documented clinically significant arrhythmias.

- Infra-tentorial tumor

- Evidence of increased intracranial pressure (clinically significant papilledema,
vomiting and nausea or reduced level of consciousness)

- Known sensitivity to conductive hydrogels

- Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not

- Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.
active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable
safety risks or compromise compliance with the protocol

- Pregnant or breast-feeding women

- Patients unwilling or unable to comply with the protocol

- Patients with leptomeningeal disease
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557